Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
While early, smaller trials showed promise by reducing infarct size (Piot et al., 2008), the larger CIRCUS trial subsequently failed to demonstrate improved clinical outcomes (Zhou et al., 2020)
Even when coverage exists, as it does for type 2 diabetes, GLP-1s are relatively inaccessible for the populations that need them most
Currently, there is no direct evidence that GLP-1RA use contributes to progression of pancreatic cysts to PDAC, but this remains an important knowledge gap for future investigations considering the high prevalence of pancreatic cysts in the general population (~ 10% by age 50 and ~25% by age 70) 56
This tension is also fueling debates about responsible prescribing and pharmaceutical advertising
GLP-1 receptor agonists are a class of medications that mimic the effects of glucagon-like peptide-1 (GLP-1), which is a hormone that helps regulate blood sugar levels
